Catalyzing Informed Action: Webinar Series & Patient Survey

The U.S. Food and Drug Administration (FDA) will host a workshop on drug development and CFS and ME on April 25-26, 2013. This FDA workshop will also serve as the first of 20 disease-specific meetings where the FDA will gather patients’ perspectives as part of a mandated “Patient-Focused Drug Development Initiative.” Learn more about the […]

Read More

New $2 Million CFS Grant Awarded to Dr. Dikoma Shungu & Team

The following press release issued today announces a new $2 million research grant to a team led by Dr. Dikoma Shungu of Weill Cornell Medical College. The award from the National Institutes of Health was made based on pilot data Dr. Shungu’s team collected with support from two pilot study grants from the Solve ME/CFS Initiative . Click here for […]

Read More

Introducing New Additions to Our 2013 Board of Directors

An active, engaged Board of Directors is at the heart of any organization’s success. It is not a passive role, but one of active leadership: defining mission, setting policy and stewarding human and financial resources. The varied talents and contacts of a board from diverse backgrounds can help an organization grow. A good board member […]

Read More

FDA Drug Development Workshop Dates Announced

This notice was posted to the FDA’s website and circulated to the Department of Health and Human Services CFS Advisory Committee’s public listserv. Inquiries should be directed to FDA at ME-CFS-Meeting@fda.hhs.gov. FDA Workshop on Drug Development for Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME) – Update The public workshop will be held on the […]

Read More

Serious Unmet Need Demands Collaborative Action

Originally posted on February 7, 2013; updated on March 4, 2013 and again on March 13, 2013 The recent decision by the Food and Drug Administration (FDA) to decline the latest New Drug Application (NDA) from Hemispherx Biopharma for Ampligen is a great disappointment to many, especially those for whom the drug has provided improved […]

Read More

The Waiting Game: Ampligen Decision Unknown

Today, Feb. 2, 2013, is the expected date for the U.S. Food and Drug Administration (FDA) to deliver its decision on the application by Hemipsherx Biopharma to market rintatolimod (Ampligen) for the treatment of chronic fatigue syndrome (CFS). The deadline for a decision is driven by the tightly regulated review calendar under FDA’s Prescription Drug […]

Read More

Manual Therapy in CFS: Part 2 of 2

By Peter C. Rowe, MD, Kevin R. Fontaine, PhD and Rick L. Violand, PT In Part 1 of this two-part series, we outlined the series of observations of patients with chronic fatigue syndrome (CFS) that has helped us develop a new approach based on advances in neurophysiology and the fields of physical therapy and osteopathic […]

Read More

Manual Therapy in CFS: Part 1 of 2

By Peter C. Rowe, MD, Kevin R. Fontaine, PhD and Rick L. Violand, PT Mark Twain loathed exercise. “Whenever I get the urge to exercise,” he is said to have remarked, “I lie down until it goes away.” He did acknowledge that his approach was not right for everyone. Beyond the intended humor of his […]

Read More

Introducing Leigh Reynolds: Our Newest Team Member

This is an exciting post to write! I am so thrilled to be joining the Solve ME/CFS Initiative as the new engagement manager. But let me begin at the beginning… My name is Leigh Reynolds and I come to the Solve ME/CFS Initiative as my next step in serving the nonprofit community. For two decades […]

Read More

CDC Stakeholder Call Coming Up

In the fall of 2012, the U.S. Centers for Disease Control and Prevention (CDC) began a new series of conference calls to update stakeholders about CFS-related research activities and other topics of interest. Information on the next call, scheduled for Jan. 14, 2013, is provided below from their listserv and website. To sign up for […]

Read More